NCT05220540 (BEST-CFA) is a clinical trial in Vascular Complications, sponsored by Semmelweis University Heart and Vascular Center.

Who is sponsoring NCT05220540?

NCT05220540 is sponsored by Semmelweis University Heart and Vascular Center.

What condition does NCT05220540 study?

NCT05220540 studies Vascular Complications.

Is NCT05220540 still recruiting?

NCT05220540 is currently completed. Last updated 21 November 2023.

Last reviewed 2023-11-21 · How we verify

NCT05220540: BEST-CFA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retrospective Analysis of Balloon Expandable Covered Stenting in the Common Femoral Artery

Completed Last updated 21 November 2023

What this trial tests

trial in Vascular Complications in 24 participants. Completed in 31 August 2023.

Timeline

1 January 2010

Primary endpoint
10 August 2023

31 August 2023

Quick facts

Lead sponsor	Semmelweis University Heart and Vascular Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	24
Start date	1 January 2010
Primary completion	10 August 2023
Estimated completion	31 August 2023
Sites	3 locations across Hungary

Conditions studied

Vascular Complications — all drugs for Vascular Complications →

Sponsor

Semmelweis University Heart and Vascular Center

Who can join

18 and older, any sex, with Vascular Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the safety and efficacy of balloon expandable covered stenting of access complications, stenoses or pseudoaneurysms of the common femoral access.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Midterm Outcome of Balloon-Expandable Covered Stenting of Femoral Access Site Complications.
Szentiványi A, Borzsák S, Süvegh A, Bérczi Á, et al · · 2024 · cited 1× · PMID 39518689 · DOI 10.3390/jcm13216550

Verify or expand the search:

Other Semmelweis University Heart and Vascular Center trials

Trials by the same sponsor.

NCT07434193 — Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergo · NA · recruiting
NCT07296965 — Oral Microbiome in Carotid Atherosclerosis · recruiting
NCT06501313 — PhotobiomoduLation for pAtientS With Advanced hEart failuRe · NA · not yet recruiting
NCT05838937 — The Usefulness of Myocardial Work IndeX in ExtraCorporeal Membrane Oxygenation Patients · not yet recruiting
NCT06173089 — REmote MOnitoring of paTiEnts witH pacEmaker or implAntable cardioverteR defibrillaTor · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05220540 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Semmelweis University Heart and Vascular Center
Last refreshed: 21 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05220540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing